Vaccine Introduction Herpes zoster is a common disease among older individuals, with a lifetime risk of 10% to 30% that rises to 50% among those living to ≥85 years [1•]. It is caused by the reactivation of latent varicella zoster virus (VZV), which can lie dormant for many ...
But fortunately, a zoster vaccine is now available which is substantially effective against both the initial chickenpox infection and shingles outbreaks. So in many parts of the world, the decision to play host to the virus is now to a certain degree discretionary. ...
very few. However, Asia-Pacific countries generally lack data on HZ vaccine safety, efficacy and cost-effectiveness. Physicians treating HZ and its complications in Asia-Pacific face familiar challenges but, with a vast aged population, Asia bears a unique and growing burden of disease. Given the...
Shingles normally self-resolves after 2 – 4 weeks, though symptoms can linger for much longer. (Where postherpetic neuraligia is evident, pain can continue for years.) But fortunately, a zoster vaccine is now available which is substantially effective against both the initial chickenpox infection ...
* vaccine (vak-SEEN) is a preparation of killed or weakened germs, or a part of a germ or product it produces, given to prevent or lessen the severity of the disease that can result if a person is exposed to the germ itself. Use of vaccines for this purpose is called immunizati...
Human alphaherpesviruses including herpes simplex viruses (HSV-1, HSV-2) and varicella zoster virus (VZV) establish persistent latent infection in sensory neurons for the life of the host. All three viruses have the potential to reactivate causing recurr
The newly registered adjuvanted herpes zoster subunit vaccine (HZ/su) has a higher efficacy than the available live-attenuated vaccine (ZVL). National decision-makers soon need to decide whether to introduce HZ/su or to prefer HZ/su above ZVL. Using a Ma
The subunit vaccine elicits stronger virus-specific CD4+ T cell response as well as antibody B cell response to gE, compared to the currently used live attenuated vaccine (Zostavax®). This situation is at variance with the current notion since a live vaccine, causing an active virus ...
Among the causes could be a lack of information, as 71% did not know the indications for the vaccine and 90% did not know how to request it. In the near future the difficulties they have experienced in prescribing vaccination could be investigated. Despite the theoretical interest in the ...